Chronic Spontaneous Urticaria: How Will Emerging Therapies Impact Treatment

340 North 3rd Street,Phoenix AZ 85004

25 February, 2022

Description

Join us in-person or virtually! Activity ChairAllen P. Kaplan, MD Professor of Medicine, The Medical University of South Carolina Charleston, SC FacultyLaura K. Ferris, MD, PhD Professor of Dermatology University of Pittsburgh Pittsburgh, PA Marc A. Riedl, MD, MS Allergist/Immunologist Clinical Director, Angioedema Center Professor of Medicine UC San Diego Health La Jolla, CA Kristin Sokol, MD, MPH, MS Allergist/Immunologist Physician Schreiber Allergy Rockville, MD OverviewUrticaria is a common skin condition characterized by the occurrence of transient pruritic wheals. Skin mast cells are the main effector cells in the pathogenesis of chronic spontaneous urticaria (CSU), but the underlying causes of their activation are unknown, and a diagnostic biomarker for CSU is still unknown. In 20% of patients with chronic urticaria, physical triggers can be identified, whereas for the remaining 80% of patients, no inducing stimulus is identified, leading to the diagnosis. Signs and symptoms of CSU and health-related quality of life (HRQoL) show moderate correlation, with some patients experiencing profound decrements in their HRQoL despite low disease activity. Thus, both QoL and disease activity must be considered when discussing treatment with patients. Despite substantial overlap between the international and US guidelines for treatment of CSU, there are differences in their recommendations, raising questions about what providers should do in the face of disagreement. Novel therapies for CSU are under investigation, which may prove to be new options for patients with CSU that does not respond to current treatments. In this activity, expert faculty will review the burden of CSU and its impact on QoL, discuss the role and clinical implications of biomarkers in CSU, compare the current major treatment guidelines, and explore the current and emerging therapies for CSU. Agenda6:30 PM Registration and Dinner 7:00 PM Introduction and Pretest Allen P. Kaplan, MD 7:05 PM Hot Topics in Chronic Urticaria: Burden of Disease, Role of Biomarkers Kristin Sokol, MD, MPH, MS 7:20 PM Case Presentation Moderated by Allen P. Kaplan, MD 7:35 PM Guidelines for CSU: Benefits and Drawbacks Marc A. Riedl, MD, MS 7:50 PM Rapid-Fire Roundtable Allen P. Kaplan, MD 7:55 PM Treating Refractory CSU Laura K. Ferris, MD, PhD 8:15 PM Rapid-Fire Roundtable Allen P. Kaplan, MD 8:20 PM Posttest and Question & Answer 8:30 PM Conclusion Learning ObjectivesUpon successful completion of this activity, participants should be better able to: Assess the burden of CSU and impact on quality of life.Evaluate the role of biomarkers in CSU and their clinical implications.Examine benefits and drawbacks of guidelines for the management of CSU including similarities and differences in the recommendations by major consensus groups.Review treatment options for patients who are refractory to first-, second-, and subsequently recommended lines of therapies.Target AudienceThe intended audience for this activity is allergists, immunologists, dermatologists, allergy physician assistants, dermatology physician assistants, allergy nurse practitioners, dermatology nurse practitioners, and other health care professionals involved in the management of patients with CSU. This non-CME educational program is provided by Vindico Medical Education. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. This program is not sponsored or programmed by the AAAAI. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This live activity is not approved for AMA PRA Category 1 Credits™. Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity. Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance. Contact Us: Email: [email protected] Privacy Policy Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086